Navigation Links
Key patent awarded to Adjuvance co-founders for pioneering method of producing rare vaccine component.
Date:11/14/2012

NEW YORK, Nov. 14, 2012 /PRNewswire-iReach/ -- Adjuvance Technologies, Inc. announced that the United States Patent and Trademark Office has granted Adjuvance co-founders a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology. Despite adjuvants' critical ability to improve the immune response to vaccine antigens, there are very few adjuvants approved for human use in the U.S.

"Before this innovative approach to producing saponin adjuvants, tedious isolation and purification protocols were necessary to obtain these materials. This work will greatly facilitate access to these promising molecules for investigators and vaccine developers" said Jeffrey Gardner, Adjuvance Technologies' CEO and co-founder. As exclusive licensee of the technology, Adjuvance will continue to focus on the commercial development of saponin adjuvants for use in innovative therapeutic and prophylactic human vaccines as well as pandemic preparedness and biodefense efforts.

"At Adjuvance, we believe this technology, which was developed at the Sloan-Kettering Institute of Memorial Sloan-Kettering Cancer Center, represents a fundamental breakthrough in vaccine adjuvant design and manufacturing. This patented technology will be able to expand and accelerate global vaccine programs that require a more secure, consistent source of these promising vaccine adjuvants," noted Mr. Gardner. U.S. Patent No. 8,283,456 was awarded to Drs. David Gin, Philip Livingston, Govind Ragupathi and others for "Triterpene saponins, methods of synthesis, and uses thereof."

About QS-21

QS-21 is a lead investigational adjuvant that has exhibited superior efficacy for a range of vaccine antigens. QS-21 has been widely used in over 100 clinical trials involving approximately 16,000 people. QS-21's ability to augment clinically significant responses to vaccine antigens has convinced GlaxoSmithKline, Johnson & Johnson, CSL and Merck to incorporate QS-21 into their drug development pipelines. In its naturally derived form, QS-21 is a semi-purified plant extract isolated by the harvesting of a rare South American tree, which translates to unique production challenges for vaccine makers. Adjuvance's new patented technology overcomes these production challenges by providing an ecologically sustainable synthetic product that is extremely pure, dependable and scalable.

About Adjuvance Technologies, Inc.

Adjuvance Technologies is a privately owned biopharmaceutical company based in New York. Adjuvance holds an exclusive license to the technology that enables the synthesis of QS-21 as well as an exclusive license to novel analogs with improved tolerability, efficacy and stability. Adjuvance has overcome natural QS-21's production challenges. Adjuvance's patented technology makes it possible to manufacture with consistently high purity and dependability synthetic QS-21 (SAPONEX) as well as an array of novel proprietary TITERQUIL saponin adjuvants on a large scale. More information is available at www.adjuvancetechnologies.com

Media Contact: Jeffrey Gardner Adjuvance Technologies, 3475594258, info@adjuvancetechnologies.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

 


'/>"/>
SOURCE Adjuvance Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Essential Medical Dismisses Patent Case against Masimo and Cercacor
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
5. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
6. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
7. Broad Patent Protection Granted for iBio Immunomodulator
8. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Somnoware, a leading provider of digital ... enables sleep physicians to create and edit their interpretation reports. This solution greatly ... familiar interface that does not require additional training to use. It also allows ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it also ... hours without sleep can compromise motor reaction time, which can increase the risk of having ... sharing the following tips from the NSF to help you sleep better and feel better:, ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
Breaking Medicine News(10 mins):